Skip to content
value.today

Pharma Solutions USA, Inc.

🇺🇸 Penn Valley, Pennsylvania, USAPharmaceuticalsFounded 2022

Formerly NavigateSOM Inc.

Total raised
$15 M
2 rounds on record
Latest round
$8 M
Mar 2026
First round on record
Jun 2023
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Pharma Solutions USA, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2026$8 MNo. 2$2 to $10 million

Pharma Solutions USA, Inc.: Raise no. 2, Mar 2026

Investors in this round

10 investors had bought by the notice of Apr 9, 2026: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Nicholas Reutell · Executive Officer
  • Sumeet Singh · Executive Officer, Director
  • Enmi Kendall · Director
  • Kevin Leininger · Director
  • Sandeep Sardana · Director
  • Sunil Shah · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amounts paid both in cash and pursuant to automatic conversion of convertible promissory notes issued prior to the offering”

Signed by Sumeet Singh, Ceo. Source: SEC Form D, newest notice filed Apr 9, 2026. Read the notice at the SEC.

equitySEC
Jun 2023$7 MNo. 1$2 to $10 million

Pharma Solutions USA, Inc.: Raise no. 1, Jun 2023

Investors in this round

11 investors had bought by the notice of Oct 25, 2024: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sumeet Singh · Executive Officer, Director
  • Enmi Kendall · Director
  • Sandeep Sardana · Director
  • Sunil Shah · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes amounts paid both in cash and pursuant to automatic conversion of simple agreements for future equity issued prior to the offering.”

Signed by Sumeet Singh, Ceo. Source: SEC Form D and 2 amendments, newest notice filed Oct 25, 2024. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Pharma Solutions USA, Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2026).

    SEC Form D · Apr 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Apr 2026

That is all the official record says: Pharma Solutions USA, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Pharma Solutions USA, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 11 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Pharma Solutions USA, Inc.
NameRoleNamed in
Nicholas ReutellExecutive officerApr 2026
Sumeet SinghExecutive officerApr 2026
Enmi KendallDirectorApr 2026
Kevin LeiningerDirectorApr 2026
Sandeep SardanaDirectorApr 2026
Sumeet SinghDirectorApr 2026
Sunil ShahDirectorApr 2026